This systematic analysis is conducted to evaluate advancements in managing extensive infantile hemangiomas (IH). The focus is on functional and aesthetic outcomes for infantile hemangiomas (IH) infants who undergo most recent treatments. IH benign vascular tumors affecting 4-10% of infants that can disrupt vital functions and present aesthetic concerns. Treatments like propranolol which is a beta-blocker have revolutionized care with 90% effectiveness but limitations persist, particularly in addressing residual scarring and tissue remodeling. Study employs a systematic review methodology under PRISMA guidelines while analyzing global IH data and therapeutic advancements and including beta-blockers, laser therapy and combination treatments. We suggest propranolol is a good option for its role in reducing IH size and severity and laser therapy enhancing results for complex cases. Combination therapies like propranolol with laser or topical agents improve efficacy while minimizing side effects and advanced techniques such as pulsed dye laser and Nd: YAG have been effective but are mostly used for residual scars. Despite improvements there are gaps remain in understanding long-term outcomes or recurrence rates and other gaps are concerning to patient satisfaction. We warrant integrated multidisciplinary approaches to improve care. Regional disparities in IH management are noted with limited access to timely diagnosis in low-income regions while future research should focus on personalized treatment strategies and safety and optimizing therapeutic combinations to enhance both functional and aesthetic outcomes. Regional disparities in IH management are noted, with limited access to timely diagnosis in low-income regions. Future research should focus on personalized treatment strategies, safety, and optimizing therapeutic combinations to enhance both functional and aesthetic outcomes.